PC
ICPT

Polar Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Polar Capital’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-60,000
Closed -$7.26M – 256
2017
Q2 		$7.26M Buy
60,000
+25,000
+71% +$2.9M 0.1% 165
2017
Q1 		$3.96M Buy
35,000
+1,500
+4% +$175K 0.06% 197
2016
Q4 		$3.64M Buy
33,500
+10,500
+46% +$1.25M 0.06% 208
2016
Q3 		$3.79M Buy
23,000
+1,131
+5% +$178K 0.07% 196
2016
Q2 		$3.12M Buy
+21,869
New +$3.19M 0.06% 205
2016
Q1 		– Sell
-13,921
Closed -$2.08M – 284
2015
Q4 		$2.08M Buy
13,921
+462
+3% +$78.2K 0.04% 213
2015
Q3 		$2.23M Buy
13,459
+3,631
+37% +$799K 0.05% 213
2015
Q2 		$2.37M Buy
9,828
+453
+5% +$121K 0.05% 220
2015
Q1 		$2.64M Buy
9,375
+1,933
+26% +$419K 0.05% 210
2014
Q4 		$1.16M Buy
7,442
+5,787
+350% +$1.07M 0.02% 229
2014
Q3 		$392K Buy
+1,655
New +$422K 0.01% 251
2014
Q1 		– Sell
-267,692
Closed -$18.3M – 279
2013
Q4 		$18.3M Buy
267,692
+87,692
+49% +$5.07M 0.43% 75
2013
Q3 		$124K Sell
180,000
-127,070
-41% -$6.27M 3.32% 2
2013
Q2 		$13.8M Buy
+307,070
New +$10.5M 0.48% 69

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Polar Capital's ICPT Position: Q3 2017 in Review

Polar Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2017, closing a stake of 60,000 shares — an estimated $7.26M sold.

Polar Capital first reported a position in ICPT in Q2 2013 and held it in 14 quarters. The position peaked at $18.3M in Q4 2013. 155 funds tracked by Wall St. Rank hold ICPT as of Q3 2017.

  • Polar Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Polar Capital sold 60,000 Intercept Pharmaceuticals, Inc. shares in Q3 2017, an estimated $7.26M.
  • Polar Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 14 quarters.
  • Polar Capital's Intercept Pharmaceuticals, Inc. position peaked at $18.3M in Q4 2013.
  • 155 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2017.

Based on Polar Capital's 13F filing for Q3 2017, filed 14 Nov 2017.